Fig. 1: Sildenafil suppresses the growth of patient-derived tumor organoids in vitro. | Communications Biology

Fig. 1: Sildenafil suppresses the growth of patient-derived tumor organoids in vitro.

From: Repurposing of phosphodiesterase-5 inhibitor sildenafil as a therapeutic agent to prevent gastric cancer growth through suppressing c-MYC stability for IL-6 transcription

Fig. 1

A Patient-derived tumor organoids (PDTOs) were successfully cultured and established from primary GC tissues in vitro, maintaining the characteristics of the primary tumor as presented by H&E staining. Moreover, IHC staining of PDE5 expression in both primary cancer tissues and corresponding PDTOs, with data represented from biological replications (n = 8). Scale bar: 20 μm. B The viability of PDTOs was tested using ATP cell viability assays following sildenafil treatment in 48 h. The IC50 values for PDTOs treated with sildenafil were calculated. Results are presented as the mean ± SD from three independent experiments (n = 3). C, D The association between PDE5 expression in PDTOs and corresponding primary GC tumor tissues, along with the IC50 values of sildenafil, was analyzed based on IHC staining results for PDE5 levels. Statistical significance is indicated as follows: ns, P value > 0.05; *, P-value < 0.05; **, P-value < 0.01; ***, P-value < 0.001.

Back to article page